Global In-Vitro Fertilization
(IVF) market is expected to reach USD 27 billion by 2022, according to a new
report by Grand View Research, Inc. The market is driven by the increasing
incidence of infertility owing to, lifestyle changes, expansion of fertility
procedures for treating male infertility such as ICSI, government initiatives
to provide better reimbursement policies, and continuous efforts by the industry
contributors.
Moreover, the availability of
genomic testing enabling the prevention of the transfer of genetic disease
during IVF use is further expected to drive the market demand. The increase in
the number of IVF treatment has led more insurance players to cover the IVF
procedures. This has ultimately led to competitive pricing and has moderated
the treatment costs as IVF has been a successfully practiced technology. This
will most likely drive the market by introducing treatment standardization and
automation.
The behavioral shift in the
society is a major factor contributing to the decreased Total Fertility Rate
(TFR). These factors include an increasing number of women in the labor force,
the increased age of the first birth, a shift from rural to urban societies,
lower marriage rates, postponement of marriage, and greater levels of education
for women.
Obesity is another factor,
which has led to an increase in infertility in the population. This is due to
the fact that the fat deposited on women’s abdomen prevents follicular
stimulation and produces male hormones. In the case of males, the rising fat
decreases testosterone levels causing a problem in sperm production. Doctors
have started recommending weight loss in men prior to fertility treatments
along with proper Body Mass Index (BMI) maintenance. The U.S. Endocrine Society
has established the use of Letrozole to increase the testosterone levels in
obese patients.
In depth research report on In-Vitro Fertilization (IVF)
Market
Further key findings from the report suggest:
·
Intracytoplasmic Sperm
Injection (ICSI) dominated the market in 2014.ICSI was introduced in the year
1992 and boosted the fertility rates from 50% to 80%, according to the American
Society for Reproductive Medicine. In April 2016, Nigeria recorded its first
successful delivery from a frozen egg. Bridge Clinic has stored the eggs using
the flash-freezing technique. With this birth, Nigeria has put itself on the
global map as it now offers IVF through frozen eggs. The eggs were then
fertilized using the ICSI technique.
·
Frozen Embryo Replacement (FER)
technique is expected to witness a rapid rise in demand. Conventionally, most
embryos were transferred through fresh cycles. However, with technology
refinement, the number of frozen embryo transfers and the success rates have
increased. Moreover, the policy of freezing the embryos has also reduced the
chances of ovarian hyper-stimulation. The frozen embryo transfers enable single
egg transfer, thus, giving enough time for the endometrial layer to heal from
the medicine stimulation effect. This ensures higher success rates.
·
Culture media dominated the
overall market in terms of revenue in 2014. With the increasing government
funding and industrial support for employees for egg/sperm freezing, the demand
for cryopreservation and the needed media for it is expected to witness growth.
There has been an increase in the research activities undertaken to improve the
culture media and to procure maximum boar sperms or eggs, spurring market
growth. Moreover, the increasing number of egg/sperm donor banks is expected to
drive the demand for sperm, egg, and embryo processing media during the forecast
period.
·
Europe dominated the IVF market
in 2014. High quality of treatment offered at the most economical price, and
the adherence to medical standards have contributed to its market leadership.
In Europe, the NHS covers three IVF cycles and has also started providing
coverage for gametes freezing. Moreover, the region is an attraction for
international clients as countries, such as Spain, have the highest number of
egg donors. The clinics also provide sex identification and other IVF
treatments, which are not offered in North America.
·
North America also accounted
for a significant share of the market in 2014. The standardization of
procedures through automation, regulatory reforms, government funding for
egg/sperm storage, and industry players introducing more IVF treatments are
some contributing factors for North America dominating the IVF market.
·
The presence of favorable
reimbursement framework (implementation of USD 50 million 5-year plans by the
U.S Department of Defense for sperm/egg freezing coverage) is also expected to
drive regional market growth over the next six years. The increasing number of
clinics undertaking newer industrial techniques to offer better fertility
success rates is also expected to boost the regional market demand.
·
The demand for IVF treatment is
expected to boom in APAC owing to fertility tourism, increasing foreign
industries trying to penetrate the economically developing countries and the
changing regulatory landscape.
·
The Asia Pacific Initiative on
Reproduction (ASPIRE), the task force of clinicians and scientists is involved
in the monitoring and management of fertility and Assisted Reproductive
Technology (ART). Such initiatives promote awareness levels thereby, driving
growth.
·
Industry contributors are
introducing newer automation to shift the IVF treatment from invasive to a
minimally invasive or non-invasive procedure. The industry players are also
trying technologies, which can enable older women to have enhanced fertility
rates. For instance, in August 2015, OvaScience announced the results of its
first published analysis comparing AUGMENT fertility treatment with a standard
IVF. The results showed a significantly higher rate of selection and transfer
of embryos as compared to the standard treatment.
·
Some key players in this market
includeEMD Serono Inc., Boston IVF, OvaScience, Thermo Fisher Scientific Inc.,
Vitrolife AB, Irvine Scientific, CooperSurgical, Inc., Cook Medical Inc., Genea
Biomedx and Progyny Inc.
Grand View Research has
segmented the In-Vitro Fertilization (IVF) market on the basis of procedures,
type of cycles, instruments, end-use, and regions:
Global In-Vitro Fertilization (IVF) Procedures Outlook
(Revenue, USD Million, 2012 - 2022)
·
Intracytoplasmic Sperm
Injection (ICSI)
·
Frozen Embryo Replacement (FER)
·
Pre-implantation Genetic
Diagnosis (PGD)
·
Others
Global In-Vitro Fertilization (IVF) Types of Cycles
Outlook (Revenue, USD Million, 2012 - 2022)
·
Fresh Donor
·
Frozen Donor
·
Fresh Non-donor
·
Frozen Non-donor
Global In-Vitro Fertilization (IVF) Instruments Outlook
(Revenue, USD Million, 2012 - 2022)
·
IVD Disposable Devices
·
Culture Media
·
Capital Equipment
In-Vitro Fertilization (IVF) Regional Outlook (Revenue,
USD Million, 2012 - 2022)
·
North America
·
U.S.
·
Canada
·
Rest of North America
·
Europe
·
Germany
·
France
·
Spain
·
Rest of Europe
·
Asia Pacific
·
Japan
·
China
·
India
·
Rest of Asia Pacific
·
Latin America
·
Brazil
·
Mexico
·
Rest of Latin America
·
Middle East and Africa (MEA)
·
South Africa
·
Rest of Middle East and Africa
Browse more research reports of this category:
About Grand View Research
Grand View Research, Inc. is a
U.S. based market research and consulting company, registered in the State of
California and headquartered in San Francisco. The company provides syndicated
research reports, customized research reports, and consulting services. To help
clients make informed business decisions, the company offers market
intelligence studies ensuring relevant and fact-based research across a range
of industries including technology, chemicals, materials, healthcare and
energy.
For more market analysis reports, please visit: http://www.grandviewresearch.com/
No comments:
Post a Comment